Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoproliferative Disorder: early-phase trial registry
6 of 14 indexed Lymphoproliferative Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 6 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Lymphoproliferative Disorder: 14 US clinical trials tracked, 6 recruiting.
Lymphoproliferative Disorder is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition lymphoproliferative-disorder
OPEN 6 | RECR 43% | LATE 3 | EARLY 6 | RANK #1230 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Lymphoproliferative Disorder lists 6 open slots (43% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoproliferative Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoproliferative Disorder is recruiting below its size-band peers.
6 of 14 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphoproliferative Disorder research.
Mayo Clinic accounts for 3 of 14 trials (21.4%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoproliferative Disorder enrolment sits around 174 participants.
Median target enrolment is 174 among the 13 trials that report a genuine target (sentinel values excluded). 6 of those (46.2%) plan for fewer than 100 participants.
-
Lymphoproliferative Disorder research is mostly interventional.
11 interventional and 3 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137643
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Mayo Clinic
NCT06630104
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Cancer Institute (NCI)
NCT03258567
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT02861417
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Cancer Institute (NCI)
NCT00092222
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
NCT00661999
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
Radiation Therapy Oncology Group
NCT00053053
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Mayo Clinic
NCT00436618
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Children's Oncology Group
NCT01000753
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013689
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoproliferative Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoproliferative Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoproliferative Disorder page
14 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Lymphoproliferative Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Lymphoproliferative Disorder trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoproliferative Disorder condition card totals 14 registered trials; most-linked intervention sodium ferric gluconate complex in sucrose; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.